SRPT — Sarepta Therapeutics, Inc.

Summary of Sarepta Therapeutics Q2 2026 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: $401 million for Q2 2026, a 34% decrease year-over-year, primarily due to lower demand for ELEVIDYS.
• Net Product Revenue: $329 million, with $231 million from the PMO franchise and $98 million from ELEVIDYS.
• Operating Income: GAAP operating income of $13 million; non-GAAP operating income of $86 million.
• Gross Margins: 75% for Q2 and 78% for the first half of the year.
• Cash and Investments: Increased by $197 million to $945 million, bolstered by strong operating performance and collaboration revenue.
• Guidance: Narrowed total net product revenue guidance for 2026 to $1.2 billion - $1.3 billion, with an upward revision of collaboration and other revenue guidance to $550 million - $600 million.

2. Strategic Updates and Business Highlights

• Commercial Portfolio: Continued stability in the PMO franchise, with ELEVIDYS showing signs of improved enrollment forms, indicating growing demand.
• Pipeline Progress: Advancements in siRNA programs for FSHD and DM1, with upcoming data readouts expected in the second half of 2026.
• Regulatory Submissions: FDA accepted supplemental NDA applications for AMONDYS 45 and VVYONDYS 53, with target action dates set for February 28, 2027.
• Cohort 8 of ENDEAVOR Study: Enrollment ongoing, with data expected in Q1 2027 to assess the impact of sirolimus on liver safety during ELEVIDYS treatment.

3. Forward Guidance and Outlook

• Revenue Expectations: Anticipate modestly lower ELEVIDYS revenue in the second half of 2026 compared to the first half, with expectations for revenue growth in 2027 as enrollment forms translate into treatments.
• Operational Focus: Emphasis on disciplined execution and capital allocation to support both commercial and R&D initiatives.

4. Challenges and Points of Concern

• ELEVIDYS Adoption: Concerns regarding the adoption of ELEVIDYS amid competition and the time lag in revenue recognition from enrollment forms.
• Market Competition: Potential competition from new exon skipping therapies could impact the PMO franchise, although management believes in the durability of their existing products.
• Regulatory Risks: The outcome of the FDA reviews for AMONDYS and VVYONDYS remains uncertain, especially in light of recent scrutiny in the industry.

5. Notable Q&A Insights

• Pipeline Excitement: CEO Michael Severino expressed enthusiasm for the siRNA programs, highlighting their potential based on strong preclinical data and the ability to achieve significant knockdown in target tissues.
• Separation of Business Units: Discussion on the potential separation of DMD and siRNA programs was met with a commitment to synergy, emphasizing the complementary nature of the two areas.
• Regulatory Strategy: For siRNA programs, the company is prepared to pursue either accelerated or traditional approval based on the evolving regulatory landscape and data outcomes.
• Cohort 8 Data: The primary focus will be on liver safety data, with expression data expected but not guaranteed in the initial release.

This summary encapsulates the key points from Sarepta's Q2 2026 earnings call, reflecting both the company's current performance and future strategic direction.